Serina Therapeutics, Inc.
SER
$3.81
-$0.09-2.31%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -96.33% | -95.90% | -98.37% | -98.22% | 2,454.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.33% | -95.90% | -98.37% | -98.22% | 2,454.21% |
| Cost of Revenue | 101.25% | 158.50% | 201.29% | 213.23% | 248.60% |
| Gross Profit | -318.95% | -935.93% | -28,203.03% | -1,070.46% | -78.63% |
| SG&A Expenses | 45.50% | 110.71% | 236.58% | 255.03% | 175.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.69% | 133.11% | 218.43% | 233.72% | 205.86% |
| Operating Income | -126.61% | -258.14% | -561.44% | -917.78% | -137.53% |
| Income Before Tax | -151.63% | -79.86% | 91.11% | -312.70% | -304.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -151.63% | -79.86% | 91.11% | -312.70% | -304.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -16.67% | 129.63% | -- | -- | -- |
| Net Income | -152.87% | -79.67% | 91.77% | -311.44% | -303.06% |
| EBIT | -126.61% | -258.14% | -561.44% | -917.78% | -137.53% |
| EBITDA | -128.93% | -264.56% | -578.97% | -967.92% | -139.90% |
| EPS Basic | 47.45% | 55.26% | 91.67% | -319.26% | -351.81% |
| Normalized Basic EPS | -36.26% | 34.83% | 100.35% | -470.20% | 2.05% |
| EPS Diluted | 58.42% | 70.49% | 96.85% | -823.33% | -1,853.13% |
| Normalized Diluted EPS | 5.49% | 42.15% | 95.83% | -4,311.33% | -252.00% |
| Average Basic Shares Outstanding | 115.51% | 196.41% | 377.38% | 332.74% | 160.15% |
| Average Diluted Shares Outstanding | 59.68% | 79.72% | 100.26% | 39.17% | 18.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |